By Nick Paul Taylor
Al Sandrock is retiring as head of R&D at Biogen. After 23 years at the company, the scientist will clear his desk by the end of the year, leaving behind a legacy of big R&D successes that are currently overshadowed by the controversial development and approval of Aduhelm.
read more
By Robert King
President Biden signed into law a roughly $1 trillion infrastructure bill that pauses a controversial rebate rule from taking effect.
read more
By Conor Hale
More than a year later, the Department of Health and Human Services has rolled back a Trump-era policy that had limited the FDA’s oversight of lab-developed tests, or LDTs, which include a wide range of in vitro diagnostics that while limited in scope, have grown in use over the past two decades.
read more
By Fraiser Kansteiner
It's official: Biocon and Viatris have launched their historic interchangeable insulin biosimilar, Semglee. The drug, which references Sanofi's blockbuster diabetes med Lantus, will roll out in a branded and unbranded format, and either version can be substituted for Sanofi's med at the pharmacy counter. But the company is using an unusual pricing strategy in a bid to pick up market share.
read more
By Nick Paul Taylor
ACTIV-3 has claimed yet another victim. Molecular Partners and Novartis are the latest companies to fail to clear the efficacy bar in the NIH-sponsored COVID-19 study, leaving their hopes for ensovibep resting on a separate trial in non-hospitalized patients.
read more
By Anastassia Gliadkovskaya
Between rising hourly rates of respiratory therapists and the global supply chain crisis, expenses at hospitals continue to pile up, leaving a grim view of 2022.
read more
By Andrea Park
Accelus was formed earlier this year after a merger between Integrity Implants and Fusion Robotics, both of which have spent years developing technology to improve minimally invasive spinal surgeries.
read more
By Joseph Keenan
The Center for Breakthrough Medicines, a CDMO founded in 2019, is getting financial backing from South Korean financial group SK Inc. to expand its manufacturing capacity.
read more
By Kyle LaHucik
AavantiBio has hired its sixth key executive this year with the addition of former bluebird bio VP Jenny Marlowe as chief scientific officer. Marlowe joins the one-year-old startup after helping bluebird submit its request to the FDA to approve a gene therapy for a certain blood disorder.
read more
By Heather Landi
The number of improper payments made under Medicare fee-for-service declined by $20.72 billion since 2014, according to new figures from the Biden administration.
read more
By Conor Hale
Medtronic secured an FDA clearance for the newest generation of its ingestible digital camera. It will serve as the basis for at-home remote diagnostics programs, which are in high-demand since the beginning of the COVID-19 pandemic.
read more
By Natalie Missakian
The Skin Cancer Foundation wanted an excuse-proof way to encourage people to get checked for melanoma and other skin cancers. So, in 2017, it launched “Destination Healthy Skin,” an RV-turned-dermatologist-office that would crisscross the country bringing free full-body skin check-ups and sunscreen samples to the masses.
read more
By Andrea Park
With colonoscopy rates plummeting amid the COVID-19 pandemic, it’s time for a new early screening method for colorectal cancer that’s less invasive and more easily accessible, while also being just as accurate as the standard test.
read more
